| http://purl.uniprot.org/citations/25281315 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/25281315 | http://www.w3.org/2000/01/rdf-schema#comment | "Nitric oxide (NO), a gaseous messenger molecule synthesized by nitric oxide synthase (NOS), plays a pivotal role in integrating dopamine transmission in the basal ganglia and has been implicated in the pathogenesis of Parkinson disease (PD). To study the role of the nitrergic system in l-DOPA-induced dyskinesia (LID), we assessed the effect of the pharmacological manipulation of NO levels and NO/cyclic guanosine monophosphate (cGMP) signaling on LID in the Pitx3(-/-) aphakia mouse, a genetic model of PD. To evaluate the effect of decreased NO signaling on the development of LID, Pitx3(-/-) mice were chronically treated with l-DOPA and 7-nitroindazole (7-NI, a neuronal NOS inhibitor). To evaluate its effect on the expression of established LID, 7-NI was administered acutely to dyskinetic mice. The chronic 7-NI treatment attenuated the development of LID in the Pitx3(-/-) mice, and the sub-acute 7-NI treatment attenuated established dyskinesia without affecting the beneficial therapeutic effect of l-DOPA. Moreover, 7-NI significantly reduced FosB and pAcH3 expression in the acutely and chronically l-DOPA-treated mice. We also examined how increasing NO/cGMP signaling affects LID expression by acutely administering molsidomine (an NO donor) or zaprinast (a cGMP phosphodiesterase 5-PDE5 inhibitor) before l-DOPA in mice with established dyskinesia. Paradoxically, the administration of either of these drugs also significantly diminished the expression of established LID; however, the effect occurred at the expense of the antiparkinsonian l-DOPA properties. We demonstrate that targeting the NO/cGMP signaling pathway reduces dyskinetic behaviors and molecular markers, but only the 7-NI treatment preserved the antiparkinsonian effect of l-DOPA, indicating that NOS inhibitors represent a potential therapy to reduce LID."xsd:string |
| http://purl.uniprot.org/citations/25281315 | http://purl.org/dc/terms/identifier | "doi:10.1016/j.nbd.2014.09.010"xsd:string |
| http://purl.uniprot.org/citations/25281315 | http://purl.uniprot.org/core/author | "Moratalla R."xsd:string |
| http://purl.uniprot.org/citations/25281315 | http://purl.uniprot.org/core/author | "Del-Bel E.A."xsd:string |
| http://purl.uniprot.org/citations/25281315 | http://purl.uniprot.org/core/author | "Espadas I."xsd:string |
| http://purl.uniprot.org/citations/25281315 | http://purl.uniprot.org/core/author | "Solis O."xsd:string |
| http://purl.uniprot.org/citations/25281315 | http://purl.uniprot.org/core/date | "2015"xsd:gYear |
| http://purl.uniprot.org/citations/25281315 | http://purl.uniprot.org/core/name | "Neurobiol Dis"xsd:string |
| http://purl.uniprot.org/citations/25281315 | http://purl.uniprot.org/core/pages | "49-59"xsd:string |
| http://purl.uniprot.org/citations/25281315 | http://purl.uniprot.org/core/title | "Nitric oxide synthase inhibition decreases l-DOPA-induced dyskinesia and the expression of striatal molecular markers in Pitx3(-/-) aphakia mice."xsd:string |
| http://purl.uniprot.org/citations/25281315 | http://purl.uniprot.org/core/volume | "73"xsd:string |
| http://purl.uniprot.org/citations/25281315 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/25281315 |
| http://purl.uniprot.org/citations/25281315 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/25281315 |
| http://purl.uniprot.org/uniprot/#_A0A0E3VL76-mappedCitation-25281315 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/25281315 |
| http://purl.uniprot.org/uniprot/#_G3UZN3-mappedCitation-25281315 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/25281315 |
| http://purl.uniprot.org/uniprot/#_O35160-mappedCitation-25281315 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/25281315 |
| http://purl.uniprot.org/uniprot/G3UZN3 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/25281315 |
| http://purl.uniprot.org/uniprot/O35160 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/25281315 |
| http://purl.uniprot.org/uniprot/A0A0E3VL76 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/25281315 |